AzTrials
AzTrials

Renal Cell CancerPhase 3NCT02684006

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

A Phase 3 study testing Avelumab (MSB0010718C), Axitinib (AG-013736) and Sunitinib in people with Renal Cell Cancer, run by Pfizer at 270 sites in 21 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Renal Cell Cancer
What is being tested?
Avelumab (MSB0010718C), Axitinib (AG-013736) and Sunitinib
Could I receive a placebo?
No, everyone receives an active treatment
How many people
886 participants
Where
270 sitesin 21 countries
Study dates
23 Mar 2016to 26 Jun 2024
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically or cytologically confirmed advanced or metastatic RCC with clear cell component
  • Availability of a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block from a de novo tumor biopsy during screening (biopsied tumor lesion should not be a RECIST target lesion). Alternatively, a recently obtained archival FFPE tumor tissue block (not cut slides) from a primary or metastatic tumor resection or biopsy can be provided if the following criteria are met: 1) the biopsy or resection was performed within 1 year of randomization AND 2) the patient has not received any intervening systemic anti-cancer treatment from the time the tissue was obtained and randomization onto the current study. If an FFPE tissue block cannot be provided as per documented regulations then, 15 unstained slides (10 minimum) will be acceptable
  • Availability of an archival FFPE tumor tissue from primary tumor resection specimen (if not provided per above). If an FFPE tissue block cannot be provided as per documented regulations 15 unstained slides (10 minimum) will be acceptable
  • At least one measurable lesion as defined by RECIST version 1.1 that has not been previously irradiated
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate bone marrow function, renal and liver functions

Who cannot join

  • Prior systemic therapy directed at advanced or metastatic RCC
  • Prior adjuvant or neoadjuvant therapy for RCC if disease progression or relapse has occurred during or within 12 months after the last dose of treatment.
  • Prior immunotherapy with IL-2, IFN-α, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
  • Prior therapy with axitinib and/or sunitinib as well as any prior therapies with other VEGF pathway inhibitors
  • Newly diagnosed or active brain metastasis
  • Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥3), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partially controlled asthma Global Initiative for Asthma 2011)
Show all 9Show fewer
  • Any of the following in the previous 12 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, LVEF less than LLN, clinically significant pericardial effusion, cerebrovascular accident, transient ischemic attack
  • Any of the following in the previous 6 months: deep vein thrombosis or symptomatic pulmonary embolism
  • Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines)

Trial locations and contacts

270 sites in 21 countries.

270 sites in 21 countries

United States93 sites
  • New York Oncology Hematology, P.C.

    Albany, New York, 12206

  • New York Oncology Hematology, PC

    Albany, New York, 12208

  • Cancer Care Associates Medical Oncology

    Allentown, Pennsylvania, 18104

  • St.Luke's Hospital-Allentown Campus

    Allentown, Pennsylvania, 18104

  • Emory University Hospital

    Atlanta, Georgia, 30322

  • Investigational Drug Service- Emory University

    Atlanta, Georgia, 30322

  • The Emory Clinic

    Atlanta, Georgia, 30322

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia, 30322

  • Rocky Mountain Cancer Centers

    Aurora, Colorado, 80012

  • University of Colorado Cancer Center Anschutz Cancer Pavilion

    Aurora, Colorado, 80045

  • University of Colorado Hospital - Clinical Trials Office (CTO)

    Aurora, Colorado, 80045

  • University of Colorado Hospital

    Aurora, Colorado, 80045

  • Oncology Investigational Drug Services- The Sidney Kimmel Cancer Center at Johns Hopkins Hospital

    Baltimore, Maryland, 21231

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21287

  • Cancer Care Associate Medical Oncology

    Bethlehem, Pennsylvania, 18015

  • St. Lukes University Health Network

    Bethlehem, Pennsylvania, 18015

  • Tower Hematology Oncology Medical Group

    Beverly Hills, California, 90211

  • St. Vincent Healthcare

    Billings, Montana, 59101

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana

    Billings, Montana, 59102

  • Massachusetts General Hospital (MGH)

    Boston, Massachusetts, 02114

  • Massachusetts General Hospital Clinical Trials Pharmacy

    Boston, Massachusetts, 02114

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115

  • Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts, 02215

  • Beth Israel Deaconess Medical Center Pharmacy - BIDMC

    Boston, Massachusetts, 02215

  • Dana - Farber Cancer Institute

    Boston, Massachusetts, 02215

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215

  • Barnes-Jewish Hospital, Siteman Cancer Center - St. Peters

    City of Saint Peters, Missouri, 63376

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio, 44106

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • New York Oncology Hematology, P.C.

    Clifton Park, New York, 12065

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado, 80907

  • James Cancer Hospital and Solove Research Institute

    Columbus, Ohio, 43210

  • The Ohio State University - GU Clinic

    Columbus, Ohio, 43210

  • The Ohio State University

    Columbus, Ohio, 43210

  • Barnes-Jewish Hospital, Siteman Cancer Center - West County

    Creve Coeur, Missouri, 63141

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas, 75246

  • Southern Cancer Center

    Daphne, Alabama, 36526

  • City of Hope National Medical Center

    Duarte, California, 91010

  • City of Hope

    Duarte, California, 91010

  • St.Luke's Cancer Center Anderson

    Easton, Pennsylvania, 18045

  • St.Luke's Hospital-Anderson Campus

    Easton, Pennsylvania, 18045

  • Baystate Franklin Medical Center

    Greenfield, Massachusetts, 01301

  • Texas Oncology - Gulf Coast

    Houston, Texas, 77024

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030

  • Investigational Product Center (IPC)

    Irving, Texas, 75063

  • Investigational Products Center (IPC)

    Irving, Texas, 75063

  • Investigational Products Center (lPC)

    Irving, Texas, 75063

  • US Oncology Investigational Products Center (IPC)

    Irving, Texas, 75063

  • New England Cancer Specialists

    Kennebunk, Maine, 04043

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, 75063

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, 89148

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, 89169

  • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy

    Long Island City, New York, 11101

  • Keck Hospital of USC

    Los Angeles, California, 90033

  • Los Angeles General Medical Center

    Los Angeles, California, 90033

  • USC IDS Pharmacy

    Los Angeles, California, 90033

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California, 90033

  • Cedars-Sinai Advanced Health Sciences Pavilion

    Los Angeles, California, 90048

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California, 90048

  • Cedars-Sinai

    Los Angeles, California, 90048

  • Joe Arrington Cancer Research and Treatment Center

    Lubbock, Texas, 79410

  • East Jefferson General Hospital

    Metairie, Louisiana, 70006

  • East Jefferson Hematology-Oncology Metairie Physician Service Inc.

    Metairie, Louisiana, 70006

  • Southern Cancer Center

    Mobile, Alabama, 36607

  • Southern Cancer Center

    Mobile, Alabama, 36608

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee, 37232

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York, 10016

  • NYU Investigational Pharmacy

    New York, New York, 10016

  • NYU Langone Medical Center

    New York, New York, 10016

  • MSKCC-Monitoring Suite

    New York, New York, 10017

  • Evelyn H. Lauder Breast and Imaging Center

    New York, New York, 10065

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065

  • Sidney Kimmel Center for Prostate and Urologic Cancers

    New York, New York, 10065

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

  • Investigational Drug Service, University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

  • Rainier Hematology-Oncology, PC

    Puyallup, Washington, 98373

  • St.Luke's Quakertown Hospital

    Quakertown, Pennsylvania, 18951

  • Mayo Clinic

    Rochester, Minnesota, 55905

  • New England Cancer Specialists

    Scarborough, Maine, 04074

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109

  • University of Washington Medical Center

    Seattle, Washington, 98195

  • Barnes-Jewish Hospital, Siteman Cancer Center

    St Louis, Missouri, 63110

  • Washington University Infusion Center Pharmacy

    St Louis, Missouri, 63110

  • Washington University School of Medicine

    St Louis, Missouri, 63110

  • Barnes-Jewish Hospital, Siteman Cancer Center - South County

    St Louis, Missouri, 63129

  • Stony Brook University-Cancer Center

    Stony Brook, New York, 11794

  • Stony Brook University

    Stony Brook, New York, 11794

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington, 98405

  • Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612

  • New England Cancer Specialists

    Topsham, Maine, 04086

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, 20007

  • Novant Health Oncology Specialists

    Winston-Salem, North Carolina, 27103

Other trials in United States

Australia24 sites
  • BHS Diagnostic Services

    Ballarat, Victoria, 3350

  • Lake Imaging

    Ballarat, Victoria, 3350

  • Box Hill Hospital

    Box Hill, Victoria, 3128

  • Eastern Health

    Box Hill, Victoria, 3128

  • Monash Health Translational Precinct, Monash Medical Centre

    Clayton, Victoria, 3168

  • Monash Medical Centre

    Clayton, Victoria, 3168

  • Monash Cancer Centre

    East Bentleigh, Victoria, 3165

  • Moorabbin Radiology

    East Bentleigh, Victoria, 3165

  • Macquarie University Hospital Pharmacy

    Macquarie University, New South Wales, 2109

  • Macquarie University

    Macquarie University, New South Wales, 2109

  • Slade Health

    Mount Waverley, Victoria, 3149

  • SKG Radiology

    Murdoch, Western Australia, 6050

  • Fiona Stanley Hospital

    Murdoch, Western Australia, 6150

  • SKG Radiology

    Murdoch, Western Australia, 6150

  • St John of God Murdoch Hospital

    Murdoch, Western Australia, 6150

  • EPIC Pharmacy Murdoch

    Perth, Western Australia, 6150

  • Nuclear Medicine Department

    Randwick, New South Wales, 2031

  • Pharmacy Department, Clinical Trials

    Randwick, New South Wales, 2031

  • Prince of Wales Hospital

    Randwick, New South Wales, 2031

  • Spectrum Medical Imaging

    Randwick, New South Wales, 2031

  • Ballarat Day Procedure Centre

    Wendouree, Victoria, 3355

  • Ballarat Oncology & Haematology Services

    Wendouree, Victoria, 3355

  • Nova Pharmacy

    Wendouree, Victoria, 3355

  • Division of Cancer Services

    Woolloongabba, Queensland, 4102

Other trials in Australia

Russia17 sites
  • RBHI "Kursk Regional Clinical Oncology Dispensary" of HCKR (legal address)

    Kursk, Kursk Oblast, 305035

  • RBHI "Kursk Regional Clinical Oncology Dispensary" of HCKR

    Kursk, Kursk Oblast, 305524

  • Scientific Research Institute of Urology named after N.A.Lopatkin of the Hersten Federal

    Moscow, 105425

  • Moscow Scientific Research Oncology Institute n.a. P.A. Hertzen

    Moscow, 125284

  • FBIH "Privolzhskiy Regional Medical Center" of FMBA

    Nizhny Novgorod, 603001

  • SBIH of Nizhegorodskaya region "Clinical-Diagnostics center"

    Nizhny Novgorod, 603006

  • FBIH "Privolzhskiy Regional Medical Center" of FMBA

    Nizhny Novgorod, 603032

  • FBIH "Privolzhskiy Regional Medical Center" of FMBA

    Nizhny Novgorod, 603109

  • SBIH of Nizhegorodskaya region "Nizhniy Novgorod Regional Clinical Oncology Dispensary"

    Nizhny Novgorod, 603126

  • Private Medical Institution "Euromedservice"

    Pushkin, Sankt-Peterburg, 196603

  • Russian Research Center for Radiology and Surgical Technologies

    Saint Petersburg, Pesochny, 197758

  • FSBI "Research Institute of Oncology n.a. N.N. Petrov" MoH RF

    Saint Petersburg, Poselok Pesochniy, 197758

  • Clinical Hospital #122 n.a. L. G. Sokolov

    Saint Petersburg, 194291

  • NS HI "Road Clinical Hospital of JSC "Russian Railways""

    Saint Petersburg, 195271

  • LLC "Diagnostic center "Energo"

    Saint Petersburg, 196247

  • LLC "Clinical Diagnostic Center "Medex-pert"

    Yaroslavl, 150014

  • SHI YR Regional Clinical Oncology Hospital

    Yaroslavl, 150040

Other trials in Russia

Japan16 sites
  • Akita University Hospital

    Akita, 010-8543

  • Chiba Cancer Center

    Chiba, 260-8717

  • Kyushu University Hospital

    Fukuoka, 812-8582

  • Hamamatsu University School of Medicine, University Hospital

    Hamamatsu, Shizuoka, 431-3192

  • Hirosaki University School of Medicine & Hospital

    Hirosaki, Aomori, 036-8563

  • Nagoya University Hospital

    Nagoya, Aichi-ken, 466-8560

  • Niigata University Medical & Dental Hospital

    Niigata, 951-8520

  • Hokkaido University Hospital

    Sapporo, Hokkaidô, 060-8648

  • Kindai University Hospital

    Sayama, Osaka, 589-8511

  • Keio University Hospital

    Shinjuku-ku, Tokyo, 160-8582

  • Tokyo Women's Medical University Hospital

    Shinjuku-ku, Tokyo, 162-8666

  • Iwate Medical University Hospital

    Shiwa-gun, Iwate, 028-3695

  • Osaka University Hospital

    Suita, Osaka, 565-0871

  • Tokushima University Hospital

    Tokushima, 770-8503

  • Yamagata University Hospital

    Yamagata, 990-9585

  • Yokohama City University Hospital

    Yokohama, Kanagawa, 236-0004

Other trials in Japan

South Korea15 sites
  • Kyungpook National University Medical Center, Clinical Pharmacy

    Daegu, 41404

  • Kyungpook National University Medical Center

    Daegu, 41404

  • Chungnam National University Hospital, Clinical Pharmacy

    Daejeon, 35015

  • Chungnam National University Hospital

    Daejeon, 35015

  • Clinical Trial Pharmacy, National Cancer Center

    Goyang-si, Gyeonggi-do, 10408

  • National Cancer Center

    Goyang-si, Gyeonggi-do, 10408

  • Seoul National University Bundang Hospital, Clinical Pharmacy

    Seongnam-si, Gyeonggido, 13620

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggido, 13620

  • Seoul National University Hospital, Clinical Pharmacy

    Seoul, 03080

  • Seoul National University Hospital

    Seoul, 03080

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722

  • Asan Medical Center

    Seoul, 05505

  • Clinical Trial Pharmacy

    Seoul, 05505

  • Samsung Medical Center Clinical Trial Pharmacy

    Seoul, 06351

  • Samsung Medical Center

    Seoul, 06351

Other trials in South Korea

United Kingdom14 sites
  • Cambridge University Hospital NHS Foundation Trust, Addenbrooke's Hospital

    Cambridge, Cambridgeshire, CB2 0QQ

  • Addenbrooke's Hospital, Central Pharmacy, Level 1

    Cambridge, CB2 0QQ

  • Beatson WOSCC

    Glasgow, G12 0YN

  • Beatson West of Scotland Cancer Centre, Gartnavel General Hospital,

    Glasgow, G120YN

  • Mount Vernon Cancer Centre, East & North Herts NHS Trust

    London, Middlesex, HA6 2RN

  • Mount Vernon Cancer Centre, Pharmacy

    London, Middlesex, HA6 2RN

  • St Bartholomew's Hospital, Barts Health NHS Trust

    London, EC1A 7BE

  • The Royal Marsden NHS Foundation Trust

    London, SW3 6JJ

  • Clinical Trials Pharmacy, The Christie

    Manchester, M20 4BX

  • Department of Medical Oncology, The Christie NHS Foundation Trust

    Manchester, M20 4BX

  • Academic Unit of Oncology, Nottingham University Hospitals NHS Trust-City Campus

    Nottingham, NG5 1PB

  • Nottingham University Hospitals, Nottingham City Hospital, Nottingham Trials Pharmacy

    Nottingham, NG5 1PB

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey, London, SM2 5PT

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey, SM2 5PT

Other trials in United Kingdom

Canada12 sites
  • Foothills Medical Centre

    Calgary, Alberta, T2N 2T9

  • Alberta Health Services - Cancer Care, Tom Baker Cancer Centre

    Calgary, Alberta, T2N 4N2

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2

  • British Columbia Cancer Agency - Sindi Ahluwalia Hawkins Centre for the Southern Interior

    Kelowna, British Columbia, V1Y 5L3

  • London Regional Cancer Program, London Health Sciences Centre

    London, Ontario, N6A 4L6

  • London Regional Cancer Program, London Health Sciences Centre

    London, Ontario, N6A 5W9

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2

  • R.S. McLaughlin Durham Regional Cancer Centre, Lakeridge Health

    Oshawa, Ontario, L1G 2B9

  • CIUSSS de l'Estrie-Centre hospitalier universitaire de Sherbrooke

    Sherbrooke, Quebec, J1H 5N4

  • Sunnybrook Research Institute

    Toronto, Ontario, M4N 3M5

  • British Columbia Cancer Agency

    Vancouver, British Columbia, V5Z 4E6

  • BC Cancer GU Clinic - Fairmont Medical Building

    Vancouver, British Columbia, V5Z IH7

Other trials in Canada

France12 sites
  • Centre Francois Baclesse

    Caen, 14076

  • Centre de Cancérologie de la Sarthe (CCS) - Clinique Victor Hugo

    Le Mans, 72000

  • Clinique Victor Hugo Centre de Cancerologie de la Sarthe

    Le Mans, 72000

  • Centre Léon Bérard

    Lyon, 69008

  • Centre Léon Bérard

    Lyon, 69373

  • Institut Paoli Calmettes

    Marseille, 13009

  • Centre Eugene Marquis Service Pharmacie - Essais Cliniques

    Rennes, Cedex, 35042

  • Centre Eugene Marquis

    Rennes, 35042

  • Institut de Cancérologie de l'Ouest - Centre René Gauducheau

    Saint-Herblain, 44805

  • Institut de Cancerologie de Lorraine (ICL)

    Vandœuvre-lès-Nancy, 54519

  • Institut de Cancerologie de Lorraine

    Vandœuvre-lès-Nancy, 54519

  • Institut Gustave Roussy

    Villejuif, 94805

Other trials in France

Netherlands12 sites
  • Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital

    Amsterdam, North Holland, 1066 CX

  • Netherlands Cancer Institute / Apotheek MC Slotervaart

    Amsterdam, North Holland, 1066 EC

  • VU University Medical Center (VUmc)

    Amsterdam, North Holland, 1081 BT

  • VU University Medical Center (VUmc)

    Amsterdam, North Holland, 1081 HZ

  • Maxima Medisch Centrum

    Eindhoven, 5631 BM

  • St Apotheek der Haarlemse Ziekenhuizen

    Haarlem, 2035 RC

  • Spaarne Gasthuis

    Hoofddorp, 2134 TM

  • Maastricht University Medical Center

    Maastricht, 6229 HX

  • Sint Franciscus Gasthuis, Pharmacy

    Rotterdam, South Holland, 3045 PM

  • Sint Franciscus Gasthuis

    Rotterdam, South Holland, 3045 PM

  • Maxima Medisch Centrum

    Veldhoven, 5504 DB

  • Maxima Medisch Centrum

    Veldhoven, 5504 DL

Other trials in Netherlands

New Zealand11 sites
  • Auckland City Hospital Pharmacy

    Auckland, 1023

  • Baxter Healthcare New Zealand

    Auckland, 1060

  • Christchurch Hospital

    Christchurch, 8140

  • Auckland City Hospital

    Grafton, Auckland, 1023

  • Waikato Hospital Pharmacy Services

    Hamilton, 3240

  • Waikato Hospital

    Hamilton, 3240

  • Wairarapa District Health Board

    Masterton, Wairarapa, 5840

  • Palmerston North Hospital

    Palmerston North, Manawatu-Wanganui, 4414

  • Broadway Radiology

    Palmerston North, 4410

  • Tauranga Hospital, Bay of Plenty Clinical Trials Unit

    Tauranga, Bay of Plenty, 3143

  • Tauranga Hospital

    Tauranga Bay of Plenty, Tauranga, 3112

Other trials in New Zealand

Israel10 sites
  • Assaf Harofe MC

    Beer Yaakov, 70300

  • Shamir Medical Center

    Beer Yaakov, 70300

  • Rambam Health Care Campus

    Haifa, 31096

  • Rambam Healthcare Campus

    Haifa, 31096

  • Meir Medical Center

    Kfar Saba, 44281

  • Rabin Medical Center

    Petah Tikva, 49100

  • The Chaim Sheba Medical Center

    Ramat Gan, 5265601

  • Pharmacy - clinical unit, Tel Aviv Sourasky Medical Center

    Tel Aviv, 6423906

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 6423906

  • The Chaim Sheba Medical Center

    Tel HaShomer, Ramat - GAN, 5265601

Other trials in Israel

Italy8 sites
  • Centro di Riferimento Oncologico - IRCCS

    Aviano, (PN), 33081

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, 20133

  • SC Farmacia

    Milan, 20133

  • Istituto Europeo di Oncologia

    Milan, 20141

  • Servizio di Farmacia

    Milan, 20141

  • Azienda Ospedaliera San Camillo Forlanini

    Rome, 00152

  • Farmacia Studi Clinici

    Rozzano, Milan, 20089

  • Istituto Clinico Humanitas

    Rozzano, Milan, 20089

Other trials in Italy

Germany5 sites
  • Universitaetsklinikum Jena

    Jena, Thuringia, 07743

  • Universitaetsklinikum Jena Klinik und Poliklinik fuer Urologie

    Jena, Thuringia, 07747

  • Universitaetsklinikum Jena

    Jena, Thuringia, 07747

  • Universitaetsklinikum Tuebingen

    Tübingen, Baden-Wurttemberg, 072076

  • Universitaetsklinikum Tuebingen

    Tübingen, Baden-Wurttemberg, 72076

Other trials in Germany

Belgium4 sites
  • Cliniques Universitaires Saint-Luc

    Brussels, 1200

  • UZ Gent

    Ghent, 9000

  • AZ Groeninge

    Kortrijk, 8500

  • CHU de Liège

    Liège, 4000

Other trials in Belgium

Romania4 sites
  • "Prof. Dr. Ion Chiricuta" Oncology Institute

    Cluj-Napoca, 400015

  • S.C. Medisprof S.R.L.

    Cluj-Napoca, 400641

  • "Sfantul Nectarie" Oncology Center

    Craiova, 200347

  • Oncomed SRL

    Timișoara, 300239

Other trials in Romania

Mexico3 sites
  • Instituto Nacional de Cancerologia

    Mexico City, Mexico City, 14080

  • Hospital Universitario Dr. Jose Eleuterio Gonzalez, Centro Universitario Contra el Cancer

    Monterrey, Nuevo León, 64460

  • Oaxaca Site Management Organization S.C.

    Oaxaca City, 68000

Other trials in Mexico

Spain3 sites
  • Hospital Universitario Ramon y Cajal

    Madrid, 28034

  • Clinica Universidad de Navarra

    Pamplona, Navarre, 31008

  • Hospital Universitario Virgen del Rocio

    Seville, 41013

Other trials in Spain

Austria2 sites
  • Krankenhaus der Barmherzigen Schwestern Wien

    Vienna, 1060

  • Medizinische Universitaet Wien

    Vienna, 1090

Other trials in Austria

Denmark2 sites
  • Herlev Hospital, Onkologisk Afdeling R

    Herlev, 2730

  • Odense Universitetshospital

    Odense C, 5000

Other trials in Denmark

Hungary2 sites
  • Dél.pesti Centrumkórház-OHII Szent Lálszló Kórház telephely

    Budapest, 1097

  • Országos Onkológiai Intézet

    Budapest, 1122

Other trials in Hungary

Sweden1 site
  • Sahlgrenska University Hospital, Dept of Oncology

    Gothenburg, 413 45

Other trials in Sweden

About this study

Official title: A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma

Being tested
Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib
Keywords
Cancer, renal cell cancer, kidney disease, kidney neoplasms, axitinib, sunitinib
Medical subject headings
Carcinoma, Renal Cell, Neoplasms, Kidney Diseases, Kidney Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Avelumab (MSB0010718C)Drug

    IV treatment Avelumab administered at 10 mg/kg IV every two weeks

  • Axitinib (AG-013736)Drug

    Also called Inlyta

    Oral treatment Axitinib given 5 mg PO BID

  • SunitinibDrug

    Also called Sutent

    Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2

Study groups in NCT02684006
Study groupRoleWhat they receive
Avelumab in combination with axitinibExperimentalAvelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
Receives: Drug: Avelumab (MSB0010718C); Drug: Axitinib (AG-013736)
SunitinibActive comparatorSunitinib given at 50 mg PO QD on schedule 4/2
Receives: Drug: Sunitinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants

    PFS: time from the date of randomization to the date of the first documentation of progressive disease (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST version [v] 1.1) or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments.

    PD was defined as at least a 20 percent (%), increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute more than (>) of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression.

    Measured: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)

  2. Overall Survival (OS) in PD-L1 Positive Participants

    OS was defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

    Measured: From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)

Secondary outcomes (32)
  1. PFS as Assessed by BICR in Participants Irrespective of PD-L1 Expression

    PFS: time from the date of randomization to the date of the first documentation of PD or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute > of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Measured: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)

  2. OS in Participants Irrespective of PD-L1 Expression

    OS was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

    Measured: From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)

  3. Percentage of Participants With Objective Response (OR) as Assessed by BICR Irrespective of PD-L1 Expression

    OR was defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.

    Measured: From date of randomization until PD (maximum up to approximately 26 months)

  4. Percentage of Participants With OR as Assessed by Investigator Irrespective of PD-L1 Expression

    OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by investigator recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.

    Measured: From date of randomization until PD (maximum up to approximately 89 months)

  5. Percentage of Participants With Disease Control (DC) as Assessed by BICR Irrespective of PD-L1 Expression

    DC was defined as a best overall response of CR, PR, non-CR/non-PD or stable disease (SD) according to RECIST v1.1 as assessed by BICR. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.

    Measured: From date of randomization until PD (maximum up to approximately 26 months)

  6. Percentage of Participants With DC as Assessed by Investigator Irrespective of PD-L1 Expression

    DC was defined as a best overall response of CR, PR, non-CR/non-PD or SD according to RECIST v1.1 as assessed by investigator. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.

    Measured: From date of randomization until PD (maximum up to approximately 89 months)

  7. Time to Tumor Response (TTR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression

    TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by BICR (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

    Measured: From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)

  8. TTR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression

    TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by investigator (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

    Measured: From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 89 months)

  9. Duration of Response (DR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression

    BICR assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression assessed by BICR or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis<10 mm). All target lesions must be assessed. PR: >=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute > of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Measured: From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)

  10. DR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression

    Investigator assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression (PD) assessed by investigator or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis<10 mm). All target lesions must be assessed. PR: >=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute > of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Measured: From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 89 months)

  11. PFS as Assessed by Investigator in Participants Irrespective of PD-L1 Expression

    Investigator assessed PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute > of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Measured: From date of randomization until PD, whichever occurred first (maximum up to approximately 89 months)

  12. Progression-Free Survival on Next-line Therapy (PFS2) in Participants Irrespective of PD-L1 Expression

    PFS2 is defined as the time (in months) from randomization to discontinuation of next-line treatment after first objective disease progression by investigator assessment, second objective disease progression by investigator assessment after initiation of next-line treatment, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute > of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Measured: From date of randomization until PD or death, whichever occurred first (maximum up to approximately 89 months)

  13. Number of Participants With Treatment-Emergent Adverse Events (AEs) Graded Based on National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (V) 4.03

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event was during the on-treatment period (time from the first dose of study treatment through 90 days after last dose of study treatment or start day of new anti-cancer drug therapy-1 day). As per NCI-CTCAE v4.03, grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death.

    Measured: From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)

  14. Number of Participants According to Grade Shift in Hematology Parameters

    Following hematology parameters were assessed: hemoglobin decreased (anemia), hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell (WBC) decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 4.03 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Baseline was defined as last assessment prior to first dose of study treatment. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.

    Measured: From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)

  15. Number of Participants According to Grade Shift in Chemistry Parameters

    Following chemistry parameters were assessed: alanine aminotransferase(ALT) increased, alkaline phosphatase(ALP) increased, aspartate aminotransferase(AST) increased, blood bilirubin increased, cholesterol high, creatinine phosphokinase(CPK) increased, creatinine increased, gamma glutamyl transferase(GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesmia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased and serum amylase increased. Laboratory abnormality graded as per NCI CTCAE v4.03; G0=non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported. Only non-zero categories for any reporting arm are reported.

    Measured: From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)

  16. Change From Baseline in Vital Signs - Blood Pressure at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit

    Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.

    Measured: Baseline (pre-dose on Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7, EOT visit (maximum up to approximately 89 months) (each cycle=42 days)

  17. Change From Baseline in Vital Signs - Pulse Rate at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and EOT Visit

    Pulse rate was measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.

    Measured: Baseline (pre-dose on Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7, EOT visit (maximum up to approximately 89 months) (each cycle=42 days)

  18. Number of Participants Who Discontinued Treatment Due to Toxicity

    Number of participants who discontinued treatment due to toxicity are reported in this outcome measure.

    Measured: From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)

  19. Time to Treatment Discontinuation/Failure Due to Toxicity

    Time to treatment discontinuation/ failure due to toxicity was defined as the time from first dose of study treatment to discontinuation of study treatment due to an adverse event or death due to study treatment toxicity.

    Measured: From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)

  20. Trough Plasma Concentration (Ctrough) of Avelumab

    Predose concentration during multiple dosing.

    Measured: Pre dose (0 hour) on Day 1, 15 and 29 of Cycle 1, Day 1 and 29 of Cycles 2, 3, 4 and Day 1 of Cycle 6

  21. Ctrough of Axitinib

    Predose concentration during multiple dosing.

    Measured: Pre dose (0 hour) on day 15 and 29 of cycle 1 (each cycle= 6 weeks)

  22. Maximum Plasma Concentration (Cmax) of Axitinib

    Measured: 2 hours post-dose on Day 1, pre-dose and 2 hours post dose on Days 15 and 29 of Cycle 1

  23. Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue

    Tumor biospecimens from pre-treatment tissue samples were analyzed by immunohistochemistry for PD-L1 biomarker expression. Number of participants with positive PD-L1 biomarker expression are reported in this outcome measure.

    Measured: At screening

  24. PFS in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups

    PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute > of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Measured: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)

  25. Percentage of Participants With OR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups

    OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

    Measured: From date of randomization until PD (maximum up to approximately 26 months)

  26. Percentage of Participants With DC in Biomarker-Positive Subgroup

    DC was defined as a best overall response of CR, PR, or stable disease (SD) according to the RECIST v.1.1 recorded from randomization until disease progression or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. SD was defined as PR that the sum increases by less than 20% from the nadir, (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.

    Measured: From date of randomization until PD or death, whichever occurred first (maximum up to approximately 26 months)

  27. TTR in Biomarker-Positive Subgroup

    TTR was defined as the time from randomization to the first documentation of objective tumor response (CR or PR) according to RECIST v1.1 which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

    Measured: From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)

  28. DR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups

    DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of PD or death due to any cause, whichever occurred first. As per RECIST version 1.1, CR: disappearance of all target and non-target lesions, and sustained for at least 4 weeks. Any pathological lymph nodes (target or non-target) must have reduction in short axis to <10 mm. PR: at least 30%< in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions. PD: defined as at least a 20% > in sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm. Appearance of one or more new lesions was also considered progression.

    Measured: From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)

  29. Number of Participants With Positive Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) of Avelumab When Used in Combination With Axitinib

    Measured: From start of treatment until 30 days after the end of avelumab treatment (maximum up to approximately 89 months)

  30. Time to Symptom Deterioration (TTD) for Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index - Disease Related Symptoms (FKSI-DRS)

    TTD was defined as the time from date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS. FKSI was used to assess symptoms and quality of life (QoL) for those diagnosed with advanced kidney cancer and it consisted of 19 questions. A 9-item subscale of the FKSI known as FKSI-Disease Related Symptoms subscale (FKSI-DRS). This subscale included 9 items: lack of energy, pain, losing weight, bone pain, fatigue, shortness of breath, coughing, bothered by fevers, and hematuria. Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher score indicated greater presence of symptoms.

    Measured: Date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS (maximum up to approximately 26 months)

  31. Change From Baseline in European Quality of Life (EuroQol) 5-Dimension 5 Levels (EQ-5D-5L) Utility Score

    EQ-5D-5L is a 5-item participant-completed questionnaire designed to assess health status in terms of a single utility score. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Overall scores ranged from 0 to 1, with low scores representing a higher level of dysfunction. Published UK weights were used to create a single summary utility score. Utility scores range from -0.594 to 1, with higher scores representing better health status.

    Measured: Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)

  32. Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Score

    EQ-VAS records the participant's self-rated health status from 0 (worst imaginable health status) to 100 (best imaginable health status), where higher scores indicated better health status.

    Measured: Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2016 (estimated)
  2. Study start23 Mar 2016
  3. Primary completion31 Aug 2023
  4. Study completion26 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
886 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02684006
Sponsor's protocol ID
B9991003
Other IDs
2015-002429-20, JAVELIN RENAL 101, 2015
Status last verified
Jul 2025
First submitted
25 Jan 2016
Last updated
30 Jul 2025
Data monitoring committee
Yes
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Tucker M, Chen YW, Voss MH, McGregor BA, Bilen MA, Grimm MO, Nathan P, Kollmannsberger C, Tomita Y, Huang B, Amezquita R, Mariani M, di Pietro A, Rini B. Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial. BMJ Oncol. 2024 Jun 12;3(1):e000181. doi: 10.1136/bmjonc-2023-000181. eCollection 2024.

    PubMed 39886142
  • Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juarez V, Rini BI, Larkin J, Nole F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol. 2025 Apr;36(4):387-392. doi: 10.1016/j.annonc.2024.12.008. Epub 2024 Dec 18.

    PubMed 39706335
  • Grimm MO, Oya M, Choueiri TK, Motzer RJ, Schmidinger M, Quinn DI, Gravis-Mescam G, Verzoni E, Van den Eertwegh AJM, di Pietro A, Mariani M, Wang J, Thomaidou D, Albiges L. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. Eur Urol. 2024 Jan;85(1):8-12. doi: 10.1016/j.eururo.2023.09.016. Epub 2023 Oct 16.

    PubMed 37852850
  • Rini BI, Atkins MB, Choueiri TK, Teresi RE, Rosbrook B, Thakur M, Hutson TE. Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma. Future Oncol. 2023 Dec;19(40):2623-2629. doi: 10.2217/fon-2023-0233. Epub 2023 Aug 1.

    PubMed 37526095
  • Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.

    PubMed 37146227
  • Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB, Schmidinger M, Penkov K, Michelon E, Wang J, Mariani M, di Pietro A, Motzer RJ. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 2023 Jun;8(3):101210. doi: 10.1016/j.esmoop.2023.101210. Epub 2023 Apr 25.

    PubMed 37104931
  • Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, Motzer RJ, Atkins MB, Haanen J, Mariani M, Wang J, Hariharan S, Larkin J. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. J Clin Oncol. 2022 Jun 10;40(17):1929-1938. doi: 10.1200/JCO.21.01806. Epub 2022 Mar 3.

    PubMed 35239416
  • Masters JC, Khandelwal A, di Pietro A, Dai H, Brar S. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma. CPT Pharmacometrics Syst Pharmacol. 2022 Apr;11(4):458-468. doi: 10.1002/psp4.12771. Epub 2022 Feb 27.

    PubMed 35166465
  • Rini BI, Atkins MB, Choueiri TK, Thomaidou D, Rosbrook B, Thakur M, Hutson TE. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2021 Oct;19(5):e306-e312. doi: 10.1016/j.clgc.2021.03.019. Epub 2021 Apr 5.

    PubMed 33947608
  • Choueiri TK, Larkin J, Pal S, Motzer RJ, Rini BI, Venugopal B, Alekseev B, Miyake H, Gravis G, Bilen MA, Hariharan S, Chudnovsky A, Ching KA, Mu XJ, Mariani M, Robbins PB, Huang B, di Pietro A, Albiges L. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open. 2021 Jun;6(3):100101. doi: 10.1016/j.esmoop.2021.100101. Epub 2021 Apr 23.

    PubMed 33901870
  • Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA, Uemura M, Pal SK, Alekseev B, Gravis G, Campbell MT, Penkov K, Lee JL, Hariharan S, Wang X, Zhang W, Wang J, Chudnovsky A, di Pietro A, Donahue AC, Choueiri TK. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020 Nov;26(11):1733-1741. doi: 10.1038/s41591-020-1044-8. Epub 2020 Sep 7.

    PubMed 32895571
  • Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO, Gurney H, Schmidinger M, Larkin J, Atkins MB, Pal SK, Wang J, Mariani M, Krishnaswami S, Cislo P, Chudnovsky A, Fowst C, Huang B, di Pietro A, Albiges L. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020 Aug;31(8):1030-1039. doi: 10.1016/j.annonc.2020.04.010. Epub 2020 Apr 25.

    PubMed 32339648
  • Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

    PubMed 30779531

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Avelumab (MSB0010718C), Axitinib (AG-013736) and Sunitinib in people with Renal Cell Cancer, run by Pfizer at 270 sites in 21 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 270 sites in United States, Australia, Russia, Japan, South Korea and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Oct 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants (time frame: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02684006, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in